Shares of Pain Therapeutics Inc. and Durect Corp. tumbled Friday after their partner Pfizer Inc. said it may not pursue further development of Remoxy, an experimental pain drug that has been plagued with delays in regulatory approval. Full story
Men who are bashful about needing help in the bedroom no longer have to go to the drugstore to buy that little blue pill. Full story
Pfizer Inc.'s first-quarter net income rose 53 percent despite falling sales, mainly because the world's second-largest drugmaker took big charges a year ago. Pfizer's results fell short of Wall Street's expectations, and the company lowered its profit and sales forecasts for the year, blaming sudde Full story
During a conference call to discuss drugmaker Pfizer Inc.'s first-quarter results, analysts asked Pfizer management about the chances they will split the New York company in two: an "innovative core" business handling Pfizer's newer medicines and development of future drugs, and a "value business" s Full story
THE RESULTS: Drugmaker Pfizer's results for the first quarter missed analysts' expectations, as generic competition cut sales by 9 percent to $13.5 billion. Net income jumped 53 percent, but only because of a one-time gain in the quarter and big charges a year earlier. Full story
(Reuters) - Shares of Pain Therapeutics Inc <PTIE.O> and Durect Corp <DRRX.O> rose more than 40 percent after partner Pfizer Inc <PFE.N> said it is in talks with U.S. health regulators to find a way forward on the companies' painkiller, Remoxy. Full story
The cholesterol-lowering drug Lipitor has generated $106 billion for its manufacturer Pfizer over the past decade. But at the end of this month, Pfizer's patent expires and lower cost generic alternatives will go on the market. NBC’s Robert Bazell has more.
People walk past the Pfizer Inc. headquarters in New York, in this January 31, 2013 file photo. Pfizer Inc reported lower-than-expected quarterly earnings and revenue April 30, 2013, and the largest U.S. drugmaker trimmed its full-year profit outlook, sending shares down 5 percent in premarket tradi
People walk past the Pfizer Inc. headquarters in New York, January 31, 2013. REUTERS/Brendan McDermid
A woman walks past the Pfizer Inc. headquarters in New York, January 31, 2013.REUTERS/Brendan McDermid
A view of the Belgian headquarters of U.S. pharmaceutical giant Pfizer, in Brussels January 23, 2007. Pfizer Inc. REUTERS/Francois Lenoir
